SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
Expanding the Prevention Toolbox
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
12 of
12
|
Introduction of Speakers Part 1
Long-Acting Cabotegravir PrEP Uptake and Persistence in a Large US Healthcare System (ABSTRACT
191)
Michael Traeger
Harvard Pilgrim Health Care Institute, Boston, MA, USA
ImPrEP CAB Brasil: Enhancing PrEP Coverage With CAB-LA in Young Key Populations (ABSTRACT
192)
Beatriz Grinsztejn
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
Estimation of Prevention-Effective CAB-LA Concentrations Among MSM/TGW in HPTN 083 (ABSTRACT
193)
Brett S. Hanscom
Fred Hutchinson Cancer Center, Seattle, WA, USA
Adherence to F/TAF in Cisgender Women Prevents HIV With Low Risk of Resistance or Diagnostic Delay (ABSTRACT
194)
Flavia M. Kiweewa
Makerere University–Johns Hopkins University Research Collaboration, Kampala, Uganda
Questions and Answers Part 1
Introduction of Speakers Part 2
Performance of HIV RNA Screening in the Context of Long-Acting Injectable Cabotegravir in HPTN 084 (ABSTRACT
195)
Sinead Delany-Moretlwe
University of the Witwatersrand, Johannesburg, South Africa
PILLAR Month 12 Clinical Results: Zero HIV Acquisition and High Persistence With CAB LA for PrEP (ABSTRACT
196)
Taimur Khan
Fenway Health, Boston, MA, USA
Response to HIV Treatment After Long-Acting Cabotegravir Preexposure Prophylaxis in HPTN 083 (ABSTRACT
197)
Raphael J. Landovitz
University of California Los Angeles, Los Angeles, CA, USA
An Injectable Multipurpose Implant With CAB and MPA for Long-Acting HIV Prevention and Contraception (ABSTRACT
199)
S. Rahima Benhabbour
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Questions and Answers Part 2
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
12 of
12
|
